Clinithink Patient Recruitment for Clinical Trials

CUSTOMER NEWS HEALTH DATA MANAGEMENT NAMES CLINITHINK AS A LEADING AI COMPANY IN HEALTHCARE. Emsp; US Head Office 1 978 296 5275 UK Head Office 44 0 292 125 0190. Secure a distinct data advantage. Type 2 diabetes mellitus. A clinical diagnosis of DKD. CLiX ENRICH for Clinical Trials. A breakthrough in patient recruitment for clinical trials. 10x The pre-screen yield in a fraction of the time. Faster time to launch. Reduce total clinical trial costs. Secure a distinct data advantage. To transform ex.

OVERVIEW

This website clinithink.com presently has a traffic classification of zero (the lower the more traffic). We have researched twelve pages within the web page clinithink.com and found sixteen websites referring to clinithink.com. We have unearthed two contacts and directions for clinithink.com to help you contact them. We have unearthed four mass media sites linked to clinithink.com. This website clinithink.com has been online for eight hundred and fourteen weeks, ten days, eighteen hours, and thirty-five minutes.
Pages Analyzed
12
Links to this site
16
Contacts
2
Locations
2
Social Links
4
Online Since
Nov 2008

CLINITHINK.COM RANKINGS

This website clinithink.com is seeing alternating quantities of traffic throughout the the year.
Traffic for clinithink.com

Date Range

1 week
1 month
3 months
This Year
Last Year
All time
Traffic ranking (by month) for clinithink.com

Date Range

All time
This Year
Last Year
Traffic ranking by day of the week for clinithink.com

Date Range

All time
This Year
Last Year
Last Month

CLINITHINK.COM HISTORY

This website clinithink.com was first filed on November 20, 2008. This web page was updated on the date of March 06, 2014. This site will go back on the market on the date of November 20, 2014. As of today, it is eight hundred and fourteen weeks, ten days, eighteen hours, and thirty-five minutes old.
REGISTERED
November
2008
UPDATED
March
2014
EXPIRED
November
2014

COMPANY MATURITY

15
YEARS
7
MONTHS
11
DAYS

LINKS TO BUSINESS

Professor From Oxford to Hope Street via Transylvania

Professor Alan Gillies MA PhD FBCS CITP Doctor Honoris Causa. Alan Gillies was Professor of Information Management at UCLAN from 1994 to 2010. Read more about Professor Alan Gillies MA PhD FBCS CITP Doctor Honoris Causa.

Evoluu healthcare technology marketing

BRINGING CLARITY TO COMPLEXITY MARKETING BRANDING COMMUNICATIONS. Our track-record of success in helping public and private sector organisations effectively articulate their vision for tomorrow gives us valuable insight into how to communicate big ideas to your audience. Evoluu is a full service agency, working with healthcare, public-sector and technology businesses around the world to help them deliver innovation.

HL7 UK - Delivering Healthcare Interoperability Standards

Guide to using HL7 Trademarks. Add me to Mailing list. It is the main forum - UK and world - where the experts in this domain come together to share experiences, views and ideas. Interoperability of health technology with members in over 55 countries. By joining HL7 UK, you gain access to our standards community,.

Multiplyd Meta-analyzing Innovations in Health Tech

The two fields are increasingly crossing paths. Multiplyd monitors changing patterns in such spaces. Read more in the Analyses. Consulting around strategy, research and new product development for Health Tech markets. A hype-free guide for investors and entrepreneurs interested in Health Tech. Print, eBook, Audio.

Scope Summit for Clinical Ops Executives 2015

Global Site Selection, Feasibility Assessment, Operations and Site Management. Enrollment Planning and Patient Recruitment. Clinical Trial Forecasting and Budgeting. Clinical IT Strategy and Governance. Managing Late Stage Research and Observational Studies. Improving Site-Study Activation and Performance. Patient Engagement, Enrollment and Retention through Communities and Technology.

WHAT DOES CLINITHINK.COM LOOK LIKE?

Desktop Screenshot of clinithink.com Mobile Screenshot of clinithink.com Tablet Screenshot of clinithink.com

CONTACTS

Clinithink

Chris Tackaberry

2-8 Scrutton Street

London, EC2A 4RT

GB

11 Internet Ltd.

Hostmaster ONEANDONE

10-14 Bath Road

Slough, BRK, SL1 3SA

GB

CLINITHINK.COM HOST

I caught that the main root page on clinithink.com took seven hundred and thirty-five milliseconds to load. We identified a SSL certificate, so our crawlers consider this site secure.
Load time
0.735 seconds
SSL
SECURE
Internet Address
104.198.102.43

NAME SERVERS

ns1.p05.dynect.net
ns2.p05.dynect.net
ns3.p05.dynect.net
ns4.p05.dynect.net

BOOKMARK ICON

SERVER OPERATING SYSTEM

I identified that clinithink.com is weilding the nginx os.

TITLE

Clinithink Patient Recruitment for Clinical Trials

DESCRIPTION

CUSTOMER NEWS HEALTH DATA MANAGEMENT NAMES CLINITHINK AS A LEADING AI COMPANY IN HEALTHCARE. Emsp; US Head Office 1 978 296 5275 UK Head Office 44 0 292 125 0190. Secure a distinct data advantage. Type 2 diabetes mellitus. A clinical diagnosis of DKD. CLiX ENRICH for Clinical Trials. A breakthrough in patient recruitment for clinical trials. 10x The pre-screen yield in a fraction of the time. Faster time to launch. Reduce total clinical trial costs. Secure a distinct data advantage. To transform ex.

CONTENT

This website had the following in the web site, "CUSTOMER NEWS HEALTH DATA MANAGEMENT NAMES CLINITHINK AS A LEADING AI COMPANY IN HEALTHCARE." Our analyzers analyzed that the web page stated " Emsp; US Head Office 1 978 296 5275 UK Head Office 44 0 292 125 0190." The Website also stated " Secure a distinct data advantage. A clinical diagnosis of DKD. CLiX ENRICH for Clinical Trials. A breakthrough in patient recruitment for clinical trials. 10x The pre-screen yield in a fraction of the time. Reduce total clinical trial costs. Secure a distinct data advantage."

OTHER WEB PAGES

Clinitrauma

Novo site da clinitrauma está no ar.

CLINITRIA Clinical Trial Services and Consulting in Central Eastern Europe

Clinical Trial Services and Consulting in Central and Eastern Europe. Advantages of Central and Eastern Europe. High enrolment rates and good patient compliance. Patients less affected by restricted therapies or other exclusion criteria.